EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Induction of peroxisome proliferation and hepatic tumors in c57bl 6n mice by ciprofibrate a hypolipidemic compound



Induction of peroxisome proliferation and hepatic tumors in c57bl 6n mice by ciprofibrate a hypolipidemic compound



British Journal of Cancer 58(1): 46-51



The hepatic effects of ciprofibrate, a potent peroxisome proliferator, were evaluated in male C57BL/6N mice, a mouse strain with very low incidence of spontaneous liver tumour development. Dietary feeding of ciprofibrate (0.0125% or 0.025% w/w) for 2 weeks resulted in marked proliferation of peroxisomes (9-fold increase) and several-fold increase (8- to 10-fold) in the activity of peroxisomal .beta.-oxidation enzymes. Feeding ciprofibrate at 0.025% concentration for 15 months followed by a 0.0125% for 6 months led to the development of hepatic adenomas in 8/14 (57%) and hepatocellular carcinomas (HCC) in 3/14 (21%) mice. In mice given 0.0125% ciprofibrate for 18 months 5 of 8 (62%) and 3 of 8 (37%) developed adenomas and HCC respectively. Similar to the findings observed in rats, both the adenomas and HCC were negative for .gamma.-glutamyltranspeptidase. The results in C57BL/6N mice of hepatocarcinogenic effect of ciprofibrate, a non-genotoxic chemical, indicate that peroxisome proliferation can be used as a reliable parameter to evaluate the carcinogenicity of hypolipidaemic compounds.

(PDF emailed within 1 workday: $29.90)

Accession: 005674299

Download citation: RISBibTeXText

PMID: 2901849



Related references

Species differences in ciprofibrate induction of hepatic cytochrome P-450 4A1 and peroxisome proliferation. Journal of Biochemical Toxicology 7(3): 183-191, 1992

Effect of dietary selenium on the induction of altered hepatic foci and hepatic tumors by the peroxisome proliferator ciprofibrate. Nutrition and Cancer 14(3-4): 261-271, 1990

Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643. Archives Internationales de Pharmacodynamie et de Therapie 234(1): 4-14, 1978

Induction by ciprofibrate of hepatic peroxisome proliferation in rats pigeons chickens cats and rhesus monkeys. Federation Proceedings 41(5): ABSTRACT 8601, 1982

Gene expression for peroxisome associated enzymes in hepatocellular carcinomas induced by ciprofibrate a hypolipidemic compound. Federation Proceedings 45(4): 970, 1986

Influence of purified diets on the induction of cell proliferation by the hepatic tumor promoters 2,2,4,4,5,5-hexachlorobiphenyl and the peroxisome proliferator ciprofibrate. FASEB Journal 17(4-5): Abstract No 711 15, March, 2003

Dose-response relationships of hepatic acyl-CoA oxidase and catalase activity and liver mitogenesis induced by the peroxisome proliferator ciprofibrate in C57BL/6N and BALB/c mice. Toxicology and Applied Pharmacology 113(2): 192-198, 1992

Characterization of the hepatic responses to the short term administration of ciprofibrate in several rat strains co induction of microsomal cytochrome p 450 iva1 and peroxisome proliferation. Biochemical Pharmacology 40(5): 1083-1094, 1990

Induction of hamster hepatic peroxisomal beta-oxidation and peroxisome proliferation-associated 80000 mol. wt. polypeptide by hypolipidemic drugs. Human Toxicology 1(2): 135-147, 1982

Peroxisome proliferation and microsomal enzyme induction by the hypolipidemic Cl-924 in rats and mice: Relationship to tumorigenicity. Fundamental and Applied Toxicology 27(2): 277-286, 1995

Immediate and delayed effects of ciprofibrate a potent peroxisome proliferator on the liver of c57bl 6n mice. Proceedings of the American Association for Cancer Research Annual Meeting 29: 83, 1988